ArticleBiochemistry and biophysics reports2025
Involvement of Activin E depletion in metabolic dysfunction-associated steatohepatitis.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beneficial Hepatokines in MASLD/MASH: Therapeutic Potentials and Drug Delivery Challenges.International journal of molecular sciences · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Activin E is a liver-derived hepatokine belonging to the transforming growth factor-β superfamily, and it promotes energy expenditure by activating brown and beige adipocytes. Activin E also possesses anti-lipolytic activity. When Activin E knockout (KO) mice are fed a high-fat diet, energy storage in adipose tissue is impaired, leading to ectopic fat accumulation in the liver. In this study, we investigated the involvement of Activin E depletion in metabolic dysfunction-associated steatohepatitis (MASH), and we characterized the phenotype of Activin E-KO mice under a high-fat diet. Despite being protected from obesity, Activin E-KO mice developed pronounced hepatomegaly, hepatic triglyceride accumulation, and histological features consistent with MASH, including steatosis, ballooning degeneration, fibrosis, and increased hepatic crown-like structures. An RNA sequencing analysis showed a gene expression signature characteristic of MASH, including upregulation of inflammatory and fibrogenic pathways. In contrast, white adipose tissue mass and adipocyte size were markedly reduced, accompanied by elevated circulating non-esterified fatty acid and insulin concentrations, indicating adipose tissue dysfunction and insulin resistance. These features were observed even in the absence of obesity, indicating a lean-type MASH phenotype. Notably, Activin E-KO female mice showed delayed disease onset, suggesting estrogen-related protection. Our findings establish Activin E as a key regulator of adipose-liver metabolic communication and suggest that its loss promotes MASH via impaired lipid storage in white adipose tissue and an increased hepatic lipid burden. High-fat diet-fed Activin E-KO mice represent a novel lean-type MASH model and may serve as a useful platform for investigating hepatokine-targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.